"With expertise
in complex pharmaceutical drug discovery, biomanufacturing,
and electronics manufacturing technologies, our highly trained
analysts investigate markets for high tech business-to-business
products and services. Our custom reports are in-depth analyses
that bring leading edge science together with profitable
business strategies for the pharmaceutical and electronics
industries." William P. Downey, President
New Report Just Published, June
2009
Biopharmaceutical Contract
Manufacturing 2009:
Expanding Markets, New Capacities and Improved Performance
This 900-page report, the comprehensive
2009 industry study, provides the latest information on biomanufacturing
strategies, markets, outsourcing, capacity utilization, contractor
relationships, new technologies including proprietary expression
systems and media, disposable bioreactors, and challenges ahead
for the industry. The data and the analysis in this report are
based on 77 in-depth interviews conducted with biomanufacturing
directors at pharmaceutical and biotechnology companies and
contractor companies worldwide. The analysis of these perspectives
and insights allow readers to make the most successful strategic
decisions. This report includes 290 summary data tables and
charts, and is the most comprehensive and current industry report
on biopharmaceutical contract manufacturing. Published June
2009.
Biopharmaceutical Contract
Manufacturing:
Best Practices Pricing Study 2008
This 300-page report documents pricing practices,
policies, agreements, and strategies for both pharmaceutical
and biotechnology companies and contract manufacturers. Learn
what pharmaceutical and biotechnology companies are paying contractors
for mammalian cell culture, microbial fermentation production,
and related services. Per- batch, per time-in-facility, and
per-gram prices are analyzed by technology and by tank sizes
and both prices paid and prices charged are documented. In addition,
the study provides detailed best practices information regarding
difficult-to-negotiate issues such as liability for failed batches,
down payments, cancellation fees, technology transfer fees,
client-caused delays, process development fees, and a lot more.
Published September 2008.
>>
Details & Order
High Throughput
Screening 2007:
New Strategies, Success Rates, and Use of Enabling Technologies
This 980-page report documents current HTS practices for drug discovery, company organizations and the evolving role
of the HTS laboratory in pharmaceutical companies, academic
centers, and institutes worldwide. The study provides
an in-depth analysis of new HTS strategies to increase
success, current and expected use of cell-based assays
and high content screening, equipment used and purchases
planned, targets and target classes growing in importance,
types of assays used and new trends, use of label-free
technologies, the number of compounds screened, throughput,
formats, budgets and expenditures by product category,
market size and growth, and the challenges in HTS for
both users and their suppliers. Published December 2007.
>>
Details & Order
Directory of Biopharmaceutical
Contract Manufacturers
The 2009 directory provides a thorough listing
of 102 contractors worldwide, including information on Type
of Services Offered, Equipment Capacity, cGMP Certification
by Service Category and more.
>>
Details & Order
The History
of High Throughput Screening for Drug Discovery:
1998-2005
HighTech Business
Decisions (HTBD) has conducted six market research studies
and published six comprehensive industry reports on high throughput
screening (HTS) since 1998. This report is specifically designed
to understand the changes that have occurred in HTS since
1998, how accurate HTS directors have been in forecasting
and predicting their use of technology and future needs, how
HTS practices have evolved, and the success of HTS as a drug
discovery tool. Topics include the number of disease targets
screened, target types, assay types, detection modes, microplate
formats, outsourcing, and other issues impacting HTS operations
and success. The complete analysis, based on both user and
supplier primary research, includes market size and growth,
major players, user strategies and requirements, documentation
of success in drug discovery, trends and technologies, and
respondents’ perceptions regarding the future of HTS.
|
